Clinical Trials Logo

Primary Peritoneal Carcinoma clinical trials

View clinical trials related to Primary Peritoneal Carcinoma.

Filter by:

NCT ID: NCT06274541 Active, not recruiting - Clinical trials for Fallopian Tube Cancer

Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study

Start date: March 22, 2019
Phase:
Study type: Observational

A pilot study to evaluate the feasibility of a NGS-based tumour BRCA1/2 mutation testing pathway initiated in the oncology clinic for patients with HGSEC, either at primary diagnosis or first relapse, whereby only patients with a positive germline BRCA1/2 mutation test will be referred to clinical genetics.

NCT ID: NCT06161272 Not yet recruiting - Ovarian Cancer Clinical Trials

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Start date: December 10, 2023
Phase: Phase 2
Study type: Interventional

This is a randomized, multicenter, two-arm, noncomparative, phase II study of fluzoparib with or without apatinib for maintenance therapy in PARPi-pretreated platinum-sensitive recurrent ovarian cancer. The primary objective is to evaluate median progression free survival of fluzoparib with or without apatinib.

NCT ID: NCT06084416 Not yet recruiting - Clinical trials for Fallopian Tube Cancer

A Study of Sovilnesib in Subjects With Ovarian Cancer

Start date: February 2024
Phase: Phase 1
Study type: Interventional

This is a randomized, phase 1b study to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of sovilnesib at different dose levels to establish the Recommended Phase 2 Dose (RP2D) of sovilnesib in subjects with high grade serous ovarian cancer (HGSOC).

NCT ID: NCT05858736 Recruiting - Colorectal Cancer Clinical Trials

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors

PRESERVE-009
Start date: July 11, 2023
Phase: Phase 1
Study type: Interventional

AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody. This is a dose escalation study to identify the maximum toxicity dose (MTD) or the recommended phase 2 dose (RP2D).

NCT ID: NCT05788484 Recruiting - Colorectal Cancer Clinical Trials

A Study of CDX-585 in Patients With Advanced Malignancies

Start date: May 11, 2023
Phase: Phase 1
Study type: Interventional

This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.

NCT ID: NCT05579366 Recruiting - Ovarian Cancer Clinical Trials

PRO1184 for Advanced Solid Tumors

PRO1184-001
Start date: December 7, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1184 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A of the study will find out how much and how frequently PRO1184 should be given to participants. Part B will use the dose and schedule found in Part A to find out how safe PRO1184 is and if it works to treat solid tumor cancers.

NCT ID: NCT05538624 Active, not recruiting - Clinical trials for Fallopian Tube Cancer

A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary

Start date: December 9, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, First-in-Human, Phase 1/2, multicenter study to evaluate the safety and efficacy of a single dose of AVB-001. AVB-001 is an encapsulated cell product engineered to produce native human interleukin-2 (hIL-2). It is delivered intraperitoneally (IP) to patients with high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.

NCT ID: NCT05537844 Recruiting - Ovarian Cancer Clinical Trials

Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma

BriTROC-2
Start date: October 27, 2021
Phase:
Study type: Observational

In BriTROC-2, up to 250 women with a confirmed diagnosis of high-grade serous/high-grade endometrioid or carcinosarcoma will be eligible for full consent (Part 2) and registration to BriTROC-2 and will be followed prospectively until first relapse. Women with presumed newly-diagnosed high-grade serous carcinoma of the ovary, fallopian tube or peritoneum can be approached for consent to Part 1 (screening consent) of BriTROC-2 prior to formal diagnosis. The aim of this study is to acquire tumour material at diagnosis and relapse, whole blood for genomic analysis and plasma for ctDNA. This study will also isolate single cells and establish organoid cultures from ascites/peritoneal washings.

NCT ID: NCT05527184 Recruiting - Endometrial Cancer Clinical Trials

First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

Start date: January 11, 2023
Phase: Phase 1
Study type: Interventional

IMGN151-1001 is a Phase 1, first in human, open-label dose-escalation and expansion study in adult patients with recurrent endometrial cancer, recurrent, high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancers.

NCT ID: NCT05483933 Enrolling by invitation - Ovarian Cancer Clinical Trials

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Start date: August 18, 2022
Phase: Phase 1
Study type: Interventional

SL03-OHD-105 is an open-label, multicenter, phase 1b trial designed to evaluate SL-172154 administered in combination with pegylated liposomal doxorubicin (PLD) or mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer. Approximately 102 patients will be enrolled in this study in two phases: dose escalation and dose expansion.